ASX Release | 23 September 2026 ASX:NXN | Nexsen Limited | ACN 655182497 1 Clear pathway defined to optimise StrepSure Highlights: • Nexsen to optimise StrepSure for FDA submission; timing anticipated to move by approx. a quarter Nexsen will incorporate the clinical learnings into an...